Swedbank AB Has $79.01 Million Stock Holdings in Boston Scientific Corporation $BSX

Swedbank AB decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 63.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 1,259,158 shares of the medical equipment provider’s stock after selling 2,170,686 shares during the quarter. Swedbank AB’s holdings in Boston Scientific were worth $79,012,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Bangor Savings Bank boosted its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BSX shares. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Citigroup decreased their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, May 28th. Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday. Finally, Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $82.12.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Up 1.6%

Shares of BSX opened at $45.30 on Wednesday. The firm’s 50-day simple moving average is $50.23 and its 200 day simple moving average is $68.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market cap of $67.33 billion, a P/E ratio of 18.95, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. Boston Scientific Corporation has a 52 week low of $42.25 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.